DOC Is One of Our Experts' Top Picks Right Now! Is Not Currently Held in Any of Our Portfolios
Fellow Investor,
My name is Kevin Matras and I am the Executive Vice President of Zacks.com. That makes me responsible for all of our popular and highly acclaimed portfolio recommendation services.
DOC is one of the tickers my team of experts is actively talking about. In fact, Ben Rains is currently holding it in his private portfolio, Alternative Energy Innovators.
He looks for innovative companies - small and large - in solar, wind, next-gen nuclear, hydrogen fuel cells, lithium, battery technology, and more. But he'll also target oil and natural gas firms aiming to revamp their legacy portfolios and diversify by joining the profit party on clean and green industries.
Today DOC is among the most promising plays in this skyrocketing space.
Would you like to find out exactly what Ben has to say about DOC, hear his projections for the future, and be notified when it's time to sell?
DOC is one of the tickers we are currently holding it in our private portfolio, Black Box Trader.
Black Box Trader uses a secret blend of stock characteristics to distill thousands of companies to a precise selection of 10 high-potential performers. This computer-driven portfolio provides a fresh list each Monday that shows what to buy and sell.
DOC fits the criteria for this service.
Now is a good time to own DOC, but would you like be notified when it's time to get out of the stock? And would you like to see real-time alerts for DOC's future buying opportunities?
Today, I'd like to give you access to that information.
What's more, you can see all the other stocks inside of Black Box Trader, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Dave Bartosiak is currently holding it in his private portfolio, Blockchain Innovators.
Blockchain Innovators targets stocks in the emerging "Internet of Money," a development that might be as earth-shattering as the Internet itself. Its market size is predicted to skyrocket from $706 million in 2017 to $60 billion in 2024 - an increase of 8,500% in 5 years.
This portfolio goes behind the hyper-volatile cryptocurrencies to tap the calmer, yet still immense profit potential of the blockchain technology that drives them.
DOC fits the criteria for this service.
Would you like to find out exactly what Dave has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Blockchain Innovators, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Jeremy Mullin is currently holding it in his private portfolio, Commodity Innovators.
He targets quick +20%-40% jumps and long-term triple-digit booms in an asset class that is often overlooked. Opportunities abound in oil, natural gas, gold, silver, coffee, hogs, corn, soybeans, cotton, lumber, orange juice, and more.
Many investors miss big profits because they don't want to get involved with futures contracts or option moves. But Zacks' unique approach lets you trade in a safer and easier way - with expert, vigilant guidance and only through stocks and ETFs.
Today DOC is among the most promising plays in the exciting world of commodities.
Would you like to find out exactly what Jeremy has to say about DOC, hear his projections for the future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks and ETFs inside of Commodity Innovators, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Jeremy Mullin is currently holding it in his private portfolio, Zacks Counterstrike.
Counterstrike aims to detect when High-Frequency Traders (HFTs) trigger irrational panic sell-offs of good stocks. This portfolio aims for double-digit gains in just 1 to 4 weeks as the companies rebound.
DOC fits the criteria for this service.
Would you like to find out exactly what Jeremy has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Zacks Counterstrike, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Neena Mishra, CFA, FRM is currently holding it in his private portfolio, ETF Investor.
ETF Investor locates the "Hidden Bulls" in any market using Zacks Industry Rank, the Zacks ETF Rank and other factors. Then it rides the emerging trends through select Exchange Traded Funds - without added risk and fees from buying stocks individually.
DOC fits the criteria for this service.
Would you like to find out exactly what Neena has to say about DOC, hear his projections for the fund's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other picks inside of ETF Investor, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact Kevin Cook is currently holding it in his private portfolio, Healthcare Innovators.
Healthcare Innovators targets the powerful "mega-trends" shaping healthcare today. This growth-oriented portfolio finds stocks from across the medical sector with exceptional long-term profit potential.
DOC fits the criteria for this service.
Would you like to find out exactly what Kevin has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Healthcare Innovators, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, David Bartosiak is currently holding it in his private portfolio, Home Run Investor.
Home Run Investor targets a diverse group of under-the-radar companies with over-the-top +50%, +100%, +200% potential while being watchful to prevent strike outs by cutting the rare losers quickly.
DOC fits the criteria for this service.
Would you like to find out exactly what David has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Home Run Investor, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Daniel Laboe is currently holding it in his private portfolio, Headline Trader.
Headline Trader targets stocks with strong fundamentals and rising earnings estimates that look to be ignited by new developments. It monitors under-the-radar reports and rumors as well as sweeping developments and breakthroughs that could lead to quick blips and sustained triple-digit gains.
DOC It monitors under-the-radar reports and rumors as well as sweeping developments and breakthroughs that could lead to quick blips and sustained triple-digit gains.
Would you like to find out exactly what Daniel has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
DOC is one of the tickers my team of experts is actively talking about. In fact, Ryan McQueeney is currently holding it in her private portfolio, Income Investor.
Income Investor is designed to balance more aggressive moves with a steady flow of income. Selected high-dividend stocks, plus other low-risk assets replace fixed-income investments that lose to inflation.
DOC fits the criteria for this service.
Would you like to find out exactly what Ryan has to say about DOC, hear her projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Income Investor, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Tracey Ryniec is currently holding it in her private portfolio, Insider Trader.
Insider Trader zeroes in on where executives and other high-ranking officers are buying blocks of their company's shares with their own money. This kind of insider buying has been shown to be one of the best indicators of a stock's future success.
DOC fits the criteria for this service.
Would you like to find out exactly what Tracey has to say about DOC, hear her projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Insider Trader, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, John Blank is currently holding it in his private portfolio, Large-Cap Trader.
Large-Cap Trader focuses on large-cap stocks that offer greater resistance to volatility than small caps, yet have comparably strong growth potential. It applies the predictive power of the Zacks Rank to find trades that get off to a fast start.
DOC fits the criteria for this service.
Would you like to find out exactly what John has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Large-Cap Trader, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, David Borun is currently holding it in his private portfolio, Marijuana Innovators.
This portfolio targets stocks at the birth of an industry when profit potential is sky-high. Legalization of marijuana is sweeping through North America and, in some form, cannabis is already approved in 33 U.S. states plus D.C. and all of Canada.
The release of pent-up demand is propelling the industry from $9 Billion in 2017 to an expected $32 billion by 2020. Marijuana Innovators pursues exceptional gains from growers, pharmaceuticals, financial firms, and suppliers of equipment, transportation and other related services to cannabis companies.
DOC is among the most promising companies in the legal cannabis industry.
Would you like to find out exactly what David has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Marijuana Innovators, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Kevin Matras is currently trading on it in his private portfolio, Options Trader.
Options Trader infuses options trading with the +23.7% yearly gain power of the Zacks Rank plus customized market-beating stock screens. This creates the potential for steady and substantial returns using only a fraction of the money you would have risked on regular stock purchases.
DOC fits the criteria for this service.
Would you like to find out exactly what Kevin has to say about DOC, hear his projections for the company's future, and be notified when it's time to make a trade?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Options Trader, PLUS I am opening up to you:
DOC is one of the toxic tickers we are currently holding it in our private portfolio, Short Sell List.
Short Sell List creates a computer-driven list of stocks about to plummet. They may look solid on the surface, but the underlying fundamentals point to disaster just ahead. DOC fits the criteria for this service.
In other words, DOC is a terrific candidate for shorting. You could make quite a bit of money as it sinks lower and lower.
Would you like to receive real-time buy and sell alerts for DOC to help you profit from the stock in future?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Short Sell List, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Brian Bolan is currently holding it in his private portfolio, Stocks Under $10.
Stocks Under $10 tracks stocks with share prices under $10 that have improving fundamentals and earnings outlooks. Each pick has potential for both immediate growth and long-term profits.
DOC fits the criteria for this service.
Would you like to find out exactly what Brian has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Stocks Under $10, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, David Bartosiak is currently holding it in his private portfolio, Surpise Trader.
Surprise Trader utilizes a Zacks' research breakthrough to isolate the most accurate analyst "whispers" to detect positive earnings surprises before they're reported. Stocks that beat earnings estimates often jump quickly in price. Surpise Trader gets you in before other traders rush in and drive up the price even more.
DOC fits the criteria for this service.
Would you like to find out exactly what Dave has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Surpise Trader, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact Kevin Cook is currently holding it in his private portfolio, TAZR.
TAZR combines pinpoint Technical Analysis with the Zacks Rank, one of the world's most powerful fundamental indicators. This portfolio brings an extra layer of timeliness and accuracy to our proven stock-rating system.
DOC fits the criteria for this service.
Would you like to find out exactly what Kevin has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of TAZR, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact Brian Bolan is currently holding it in his private portfolio, Technology Innovators.
Technology Innovators targets breakthrough stocks and emerging trends in the fast-growing tech sector. This portfolio targets long-term triple-digit profit potential.
DOC fits the criteria for this service.
Would you like to find out exactly what Brian has to say about DOC, hear his projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Technology Innovators, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Sheraz Mian chose it for his private portfolio, Zacks Top 10 Stocks.
Zacks Top 10 Stocks compiles the best 10 stocks to buy and hold throughout the year. Each pick comes with in-depth research, and is actively managed, with quarter updates.
DOC fits the criteria for this service.
Would you like to find out exactly what Sheraz has to say about DOC and hear his projections for the company's future?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Zacks Top 10 Stocks, PLUS I am opening up to you:
DOC is one of the tickers my team of experts is actively talking about. In fact, Tracey Ryniec is currently holding it in her private portfolio, Value Investor.
Value Investor combines proven value criteria with Zacks Rank timing. It tracks undervalued companies until the market starts to see their real worth, then pounces for gains that can build for several years.
DOC fits the criteria for this service.
Would you like to find out exactly what Tracey has to say about DOC, hear her projections for the company's future, and be notified when it's time to sell?
I'd like to share that information with you today.
What's more, you can see all the other stocks inside of Value Investor, PLUS I am opening up to you:
At any given time, our experts are recommending 200 or more tickers in our suite of private portfolios. Right now, DOC doesn't make the cut.
But...
Would you like to see which stocks our experts ARE talking about today?
Starting today, I am opening up to you:
- All of our recommendation portfolios
- All of our private market insights
- All of our real-time buy and sell signals
All for a grand total cost of just $1. And not 1 cent of additional obligation.
We call this combination of high-powered portfolios Zacks Ultimate.
How can I bring you all this for $1?
The value stems from our proprietary stock-rating system, the Zacks Rank, and its average gain of +23.7% per year since 1988. These proven results give me a steadfast conviction that once you start using our profitable trades, it will become a very hard habit to break.
In other words, you will want to continue beyond one month because our Zacks Rank stock-picking system flat out works. It has worked for more than a quarter century. It has worked through bullish, bearish and range-bound markets.
In fact, despite three full-blown recessions and numerous bear markets, our system has more than doubled the S&P 500.
Think about it. How many money managers, brokerage firms, mutual funds or investment newsletters can substantiate a return like that?
What can +23.7% per year mean to you and your portfolio?
If you invested just $10,000 in the S&P 500 in 1988 and rebalanced it monthly, you would have more than $450,000 today. Quite a nice gain.
But suppose instead you had put that same $10,000 into our Zacks Rank system, it could have compounded to more than $24.0 million dollars.
A truly life-changing difference.
Why does the Zacks Rank system work so well?
It's unbiased and purely mathematical. It doesn't depend on someone's whim or on which CEOs are appearing on TV. Instead, our formula is based on what researchers have proven to be the most powerful force that impacts stock prices: Earnings Estimate Revisions.
- From short-term trading to long-term investing.
- From value to growth.
- From fundamental to technical.
- From stable income to hot momentum.
See them all, and then settle on the portfolio strategies that best fit your personal investment style and goals.
To find them, we constantly monitor analysts at more than 150 brokerage firms. When they revise their earnings estimates upward for a company, its stock price tends to rise significantly over the next one to three months.
That's the central truth that animates the Zacks Rank. And I am confident that you will want to take advantage of it, not just for one month, but for many years to come.
But, first things first. Starting now, for only $1, you may sample all of our portfolio strategies that harness the power of the Zacks Rank and Earnings Estimate Revisions:
Here's a glimpse of the portfolio email alerts that will be available to you...
Alternative Energy Innovators
Tracks companies racing to dominate industries with epic upside - solar, wind, next-gen nuclear, lithium, hydrogen fuel cells, battery technology, and more.
Currently closed to new investors (but not to you).
Black Box Trader
Gain access to Zacks' 100% computer-driven portfolio. Each Monday morning, this secret formulation distills a list of 10 stocks with extreme gain potential.
Blockchain Innovators
We'll pursue massive gains from the booming "Internet of Money" much like those who profited from gold rush prospectors by selling picks and axes. Our strategy is to avoid the breakneck volatility of Bitcoin and other cryptocurrencies by focusing on the blockchain technology that powers them.
Commodity Innovators
We'll seek both short and long-term profits on oil, gold, livestock, grains, currencies, and more at reduced risk. No futures or options, just easy-to-trade stocks and ETFs.
Currently closed to new investors (but not to you).
Counterstrike
When High-Frequency Traders (HFTs) trigger panic sell-offs of good stocks, Zacks selectively strikes back. We'll ride the best of those pushed-down companies as they rebound to the price levels they deserve. Our aim is for double-digit gains in just 1 to 4 weeks.
Currently closed to new investors (but not to you).
Headline Trader
Our new fast-reflex Headline Trader portfolio jumps on news from under-the-radar quarterly reports and pending acquisitions to sweeping industry trends and breakthroughs.
It's currently closed to new investors (but not to you).
Home Run Investor
Turn up the best Zacks Rank growth stocks for the long haul. This portfolio discovers companies with robust earnings momentum that leads to a string of quarterly earnings surprises and a thriving share price.
Income Investor
Leverage the Zacks Rank to find the best dividend-paying stocks for the long haul. Toss in some selected income-producing investments and you get outperformance with a smoother ride and lower risk.
Large-Cap Trader
Balance your small-cap stock holdings with larger, more substantial companies that are less likely to be shaken by a bad headline or market dip. This portfolio applies Zacks Rank timeliness and strategic perspective for strong gain potential along while enjoying a better night's sleep.
Insider Trader
Track when key officers dip into their own pockets to snap up shares of their own companies. When this signal is combined with Zacks Rank fundamentals, there is no better tip-off to the future success of a stock.
Currently closed to new investors (but not to you).
Marijuana Innovators
Cannabis legalization is sweeping through North America, igniting the industry from billion in 2017 to an expected billion by 2020. Zacks shows which stocks to ride and which to shun.
Currently closed to new investors (but not to you).
Options Trader
Blend winning options strategies with the Zacks Rank to pursue timely and substantial gains. A bonus is that you'll use only a fraction of the money you would have risked on traditional stock purchases.
TAZR
Our Technical Analysis + Zacks Rank portfolio offers the best of both worlds. No need to base investment decisions solely on technical price action or on fundamentals. Now both successful approaches are combined to multiply the timeliness and profit potential of each recommended trade.
Technology Innovators
Rapid advances in technology have had an undeniable impact on the world, the economy and the stock market. This portfolio tracks breakthrough companies and emerging trends such as artificial intelligence, cloud computing, the Internet of Things and more. Deep research plus the Zacks Rank and other indicators are used to select stocks with long-term triple-digit gain potential.
Value Investor
Track stocks that are selling at 25-50% discounts and pounce just as the market is starting to notice their attractiveness. This portfolio patiently rides winners to their maximum long-term potential.
ETF Investor
Focus on a select handful of Exchange Traded Funds to pursue maximum gains. This portfolio will pinpoint the most promising market trends with the very best ETFs to ride them, without added risk and fees from buying stocks individually.
Zacks Premium
Command an array of professional-strength tools that are easy to use for individual investors. Use them to evaluate your portfolio, find better stocks and funds, and track your investments to sell when the time is right.
Stocks Under
This portfolio finds companies with low share prices that have improving fundamentals and earnings outlooks. It uses the Zacks Rank, and other key metrics, to find those rare few stocks with the most explosive upside potential. We buy early when the rest of Wall Street is still asleep at the wheel and then ride these winners for maximum long-term gains.
Surprise Trader
Isolate the most accurate analyst "whispers" to detect positive earnings surprises BEFORE they're reported. This strategy's tested accuracy is an unprecedented 77.32%. When alerted to "surprise stocks" before Wall Street can react to them, you can fully ride their price pops.
Currently closed to new investors (but not to you).
Zacks Top 10 Stocks
Receive our annual service that provides the best buy and hold picks for the year ahead.
So what happens after your 30-day Zacks Ultimate $1 experience is over?
Right now you might be thinking, "Aha, here comes The Catch."
Well, there really isn't one. You don't have to spend another cent.
We offer Zacks Ultimate as nothing more than your personal "investing showroom" where you can look under the hood of our high-performance portfolio services. Then, join the ones that suit you best. Or join none at all.
The choice is completely up to you.
Will this be hard work? Will you receive too much information?
Not at all. Most of our members start by quickly scanning each of the portfolios to narrow down to the few that suit them best. Then, for the next 30 days, they enjoy the real-time recommendations from just those services while side-stepping the others.
It could not be easier to get exactly what you want to improve your investment success.
And if you have any questions or need any help sorting out which portfolios are best for you, just pick up the phone and talk to a real person who can give you the info you need. It's like having a personal guide to help you zero in on the services that match your investing goals and style.
And then, after your 1 month trial, you have three simple choices:
1. Walk out of the showroom anytime you please and not pay one cent more.
2. Continue your see-it-all Zacks Ultimate subscription for only $299 a month.
3. Join just one or more of the individual portfolios.
Once again, the choice is entirely up to you.
Backed by 2 Airtight Guarantees
![Satisfaction Guarantee Shield](https://staticx-tuner.zacks.com/woas/adv/services/images/seals/performance-guarantee-shield.png)
And don't worry, you are covered by a Satisfaction Guarantee. You may cancel up to 90 days after your trial is over. And if you feel we have not exceeded your expectations, then we will refund every last cent - including the $1 you paid for the trial. No problem.
But that isn't the half of it.
![Perfomance Guarantee Shield](https://staticx-tuner.zacks.com/woas/adv/services/images/seals/performance-guarantee-shield.png)
You're also backed by a full-year, money-back Performance Guarantee. Details. That means if we don't help you beat the market, we don't deserve your money.
No one else offers a combination of money-back assurances like these. That's because no one else has a proven system like the Zacks Rank that beats the market so consistently, year after year.
Join online right now or call us M-F 10am-6pm ET at 1.888.775.8348. Outside the U.S., 1.312.265.9309.
Don't miss your chance to sample all of our strategies that are designed to make money for you, regardless of market direction, regardless of volatility.
Over the next 30 days, I look forward to helping you discover the impact that the Zacks Rank and Earnings Estimate Revisions can have on your portfolio.
Thank you, and good investing,
Kevin Matras
Executive Vice President
Zacks Investment Research